mRNA Cancer Medicines for Every Patient

Teaching the immune system to find cancer and fight it.

Cancer hides from the immune system. ImmunoScript makes mRNA-based immunotherapies that carry two kinds of instructions at once.

IS-001 Cytokines Call immune cells in and activate them Tumor antigens Show immune cells what to attack 5 cytokine mRNAs 3 tumor-associated antigen mRNAs

Lasting

Builds immune memory that keeps watch long after treatment ends.

Off the shelf

Made in advance and ready the day a patient needs it.

Multiplexed

Eight mRNAs in one therapy take on both of cancer's defenses at once.

Why now

The era of mRNA cancer medicine has begun.
What's missing is an effective off-the-shelf option.

Proven

mRNA works at global scale

mRNA medicines can be designed quickly and made for millions.

Working

Personalized mRNA is fighting cancer

Custom-made mRNA treatments are helping patients in clinical trials. But each one is built for a single person, and that takes weeks.

Missing

An effective off-the-shelf immunotherapy

A ready-made mRNA immunotherapy for a broad patient population, available as soon as needed. That is the gap ImmunoScript is built to fill.

How it works

Two barriers. One therapy.

Tumors block immune cells at two steps: getting in and recognizing the cancer. Our lead therapy, IS-001, unlocks both.

Pipeline

Starting with pancreatic cancer.
Built to expand to other solid tumors.

IS-001 is our lead therapy targeting pancreatic cancer.

Program
DiscoveryPreclinicalIND-enablingPhase 1
IS-001Lead indication: pancreatic cancerA multiplexed mRNA therapy combining 5 cytokines and 3 tumor antigens.Stage: Preclinical
IS-002Lead indication: solid tumors (undisclosed)Stage: Discovery

Results

What IS-001 achieved in preclinical studies.

Tested in aggressive mouse models of pancreatic cancer.

50%

Complete response rate

In half of treated mice, tumors were completely eliminated.

1 year

Cancer-free

Complete responders stayed cancer-free for a year, long after treatment stopped.

Lasting

Immune memory

The immune system learned to recognize the cancer and kept watch, so tumors did not return.

Published in Nature Communications (2026).

Team

Founded by the scientists behind the science.

Chaitanya Parikh

Chaitanya Parikh, PhD

Co-Founder & CEO

PhD in Cancer Biology, UMass Chan Medical School.

LinkedIn
Marcus Ruscetti

Marcus Ruscetti, PhD

Co-Founder & Chief Scientific Advisor

Associate Professor, UMass Chan Medical School.

LinkedIn

Publications

Peer-reviewed science.

2026

Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer

Parikh CN, et al., Ruscetti M. Nature Communications 17, 7618 (2026).

Read in Nature Communications

Investors & partners

Let's talk about IS-001.

If you're interested in investing in or partnering on the next generation of cancer immunotherapy, send us a note. We read every message and reply personally.

We are also in early discussions to identify potential clinical trial sites. If you're a physician interested in IS-001, we'd be glad to hear from you.

Careers

We're always looking for exceptional people.

Across science, regulatory and business development. If you want to help build the next generation of cancer medicines, we'd love to hear from you.

Get in touch

Contact us

Let's bring this therapy to patients, together.

Patients, clinicians, investors, partners and scientists: we'd love to hear from you.

Email
Location

Mansfield Bio-Incubator (BioInc)
Mansfield, Massachusetts

Follow

ImmunoScript on LinkedIn